|
Immuron Limited (NASDAQ: IMRN) |
|
Immuron Limited
IMRN's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Immuron Limited growth rates, revenue grew
in IV. Quarter 2023 from the same quarter a year ago.
Ranking at No. 735
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -8.1 %
• More on IMRN's Growth
|
|
Immuron Limited realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.21 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.08.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.42.
• More on IMRN's Valuation
|
|
|
|
|
Immuron Limited realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.21 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 3.08.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.42.
Immuron Limited Price to Book Ratio is at 0.23 lower than Industry Avg. of 82.31. and higher than S&P 500 Avg. of 0.02
• More on IMRN's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com